Loading Events

« All Events

  • This event has passed.

Jared J. Grantham Symposium – 2022 “The Future of PKD Research”

June 10

Jared J. Grantham Symposium – 2022
“The Future of PKD Research”
Friday, June 10th, 8:30am – 12:30pm CST
Please click the link below to Register for the webinar:
https://us02web.zoom.us/webinar/register/WN_sXF_9I0dQxyIwUvGBjfVeQ

8:30 – 8:35am Welcome
Alan Yu, MB, BChir, Director, Jared Grantham Kidney Institute and Division of Nephrology
8:35 – 8:45am Introductory Remarks – History of the Grantham Symposium and Presentation of Artwork
Jim Calvet, PhD, University Distinguished Professor, Biochemistry, Kansas PKD Center Director
8:45 – 9:30am
Alessandra Boletta, PhD
Head, Molecular Basis of Cystic Kidney Disorders Unit
Division of Genetics and Cell Biology
San Raffaele Scientific Institute, Milan, Italy
“Metabolic Reprogramming in Polycystic Kidney Disease”
Dr. Alessandra Boletta graduated in Biology from the University of Pavia,
Italy. She carried out her doctoral training at the Mario Negri Institute in
Bergamo, Italy, working on gene delivery to the kidney. She then went to
Johns Hopkins University for her postdoctoral training. Here, she began her
scientific activity on Polycystic Kidney Disease, working on heterologous
expression of Polycystin-1 aimed at establishing cellular models to investigate
its function.
With support from a Telethon Career Program and a Marie Curie Excellence
Award, Dr. Boletta moved back to Italy to establish her lab at the San Raffaele
Scientific Institute in Milan. Here, she took on the position of Director for the
Division of Genetics and Cell Biology (2014-2019), and she is currently Head
of the Research Unit. Over the years, her lab has developed several cellular
and animal models to study the functions of the polycystins and the
pathophysiology of ADPKD. Her laboratory has identified metabolic
reprogramming as an important feature of the disease, offering several new
options for therapy as well as novel insights into the pathogenesis of ADPKD.
She currently serves on the PKD Foundation Scientific Advisory Panel. Dr.
Boletta received the Lillian Jean Kaplan Award in 2022.

9:30 – 9:40am: Break

9:40 – 10:25am
Albert Ong, DM, MA, FRCP
Professor of Renal Medicine and Head, Academic Nephrology
Department of Infection, Immunity and Cardiovascular Disease
University of Sheffield Medical School, United Kingdom
“Understanding Biological Variation in ADPKD: Lessons
from Nature”
Dr. Albert Ong is Professor of Renal Medicine and Head of Academic
Nephrology at the University of Sheffield, UK. Born in Malaysia, he was
educated at the University of Oxford, completing postgraduate clinical and
research training in nephrology at University College London and Oxford
before taking up his present post. Work from his group has contributed to
our fundamental understanding of the nature and functions of the ADPKD
proteins, polycystin-1 and polycystin-2, in health and disease. Current areas
of active research are in the role of cytoskeletal dysregulation in cystogenesis
and the potential of small RNA molecules as disease biomarkers and
therapeutic targets. Dr. Ong received the Lillian Jean Kaplan Award in 2022.

 

10:25 – 10:35am: Break
10:35 – 11:20am
Arlene Chapman, MD
Professor of Medicine and Chief, Section of Nephrology
Director, Clinical Research Center, Institute for Translational Medicine
University of Chicago Medical Center
“ADPKD – Membership in the Cysterhood”
Dr. Arlene Chapman is Professor of Medicine, Chief of Nephrology, University
of Chicago, and has spent the last 35 years evaluating clinical manifestations
and therapeutic interventions in ADPKD. Dr. Chapman’s research focuses on
mechanisms of cyst formation in ADPKD, and she has been integrally involved
in the development of novel imaging biomarkers for this disease. Dr.
Chapman also studies personalized or precision medicine and the role that
genetic background plays in predicting antihypertensive responses to blood
pressure medications used to treat hypertension. Her work has covered the
areas of hypertension, intracranial aneurysms, disease progression, htTKV as
an imaging biomarker, metabolomic and urinary biomarkers in ADPKD and
treatment strategies including vasopressin V2 receptor antagonists. Dr.
Chapman received the Lillian Jean Kaplan Award in 2020.
11:20 – 11:40 Break
11:40 – 12:25 Roundtable Discussion on “The Future of PKD Research”
Moderated by Darren Wallace, PhD, Professor, Internal Medicine, Kansas PKD Center Co-Director
12:25 – 12:30 Closing Remarks – Alan Yu